Decision

Alteplase for treatment of acute ischaemic stroke: independent review

The review of alteplase in the treatment of acute ischaemic stroke by the expert working group of the Commission on Human Medicines.

From:
Medicines and Healthcare products Regulatory Agency
Published
24 July 2015

Documents

PDF, 306 KB, 44 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 482 KB, 28 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 1.23 MB, 52 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 2.37 MB, 162 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 3.54 MB, 179 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 5.15 MB, 113 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 463 KB, 37 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 3 MB, 271 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 318 KB, 29 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The Commission on Human Medicines (CHM) has fully endorsed the conclusions and recommendations of the expert working group on alteplase in the treatment of stroke, confirming that the benefit of alteplase outweighs the risk when used up to 4.5 hours after symptoms appear.

The commission supported full transparency and the publication of all information considered by the group. Some information has been redacted to protect the identity of individuals and details of unpublished data.

The group considered the data above to reach their conclusions.

See the for more details on alteplase.

Updates to this page

Published 24 July 2015

Sign up for emails or print this page

Related content